Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.60 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 5/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.50 |
| ▸ | AURKA | O14965 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745294 | 1.00 | PDE5A (0.60) | PDE5ANUDT1PDE4APDE4BPDE4C | |
| SCHEMBL10695892 | 0.88 | PDE5A (0.60) | PDE5ANUDT1PDE4APDE4BPDE4C | |
| SCHEMBL23122458 | 0.84 | AURKA (0.58) | PDE5ANUDT1PDE4APDE4BPDE4C | |
| SCHEMBL10695856 | 0.83 | PDE5A (0.61) | PDE5ANUDT1PDE4APDE4BPDE4C | |
| SCHEMBL27678090 | 0.82 | AURKA (0.56) | PDE5ANUDT1PDE4APDE4BPDE4C | |
| SCHEMBL10697822 | 0.80 | NUDT1 (0.47) | PDE5ANUDT1PDE4APDE4BPDE4C | |
| SCHEMBL2314765 | 0.76 | DDAH1 (0.55) | PDE5ANUDT1PDE4APDE4BPDE4C | |
| SCHEMBL15066222 | 0.74 | LMNA (0.55) | PDE5ANUDT1PDE4APDE4BPDE4C | |
| SCHEMBL2675687 | 0.74 | DDAH1 (0.56) | ALDH1A1KMT2AHPGDTP53NPC1 | |
| SCHEMBL4365099 | 0.74 | CBFB (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0254588-A1 | Imidazo[4,5-b] pyridine compounds, process for preparing same and pharmaceutical compositions containing same | TOKYO TANABE COMPANY LIMITED (JP) | 1988-01-27 | — | — | EP | claimed |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| EP-4031532-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787136-A | Substituted benzimidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021055591-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, CLN6 | PDE5A 2578/4885NUDT1 481/4885PDE4A 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.